Pilot prospective evaluation of 18F-FPPRGD2 PET/CT in patients with cervical and ovarian cancer

Biodistribution of the 18F-FPPRGD2 PET radiopharmaceutical in cancer patients: an atlas of SUV measurements

(2015) Ryogo Minamimoto et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Glioblastoma Multiforme Recurrence: An Exploratory Study of18F FPPRGD2PET/CT

(2015) Andrei Iagaru et al.   RADIOLOGY

Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer

(2014) Martin R. Stockler et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival with Bevacizumab in Advanced Cervical Cancer

(2014) Krishnansu S. Tewari et al.   NEW ENGLAND JOURNAL OF MEDICINE

18F-FPPRGD2 PET/CT: Pilot Phase Evaluation of Breast Cancer Patients

(2014) Andrei Iagaru et al.   RADIOLOGY

First Experience with Clinical-Grade [18F]FPP(RGD)2: An Automated Multi-step Radiosynthesis for Clinical PET Studies

(2011) Frederick T. Chin et al.   MOLECULAR IMAGING AND BIOLOGY

Antiangiogenic therapy: impact on invasion, disease progression and metastasis

(2011) John M. L. Ebos et al.   Nature Reviews Clinical Oncology

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

(2011) Robert A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pilot Pharmacokinetic and Dosimetric Studies of18F-FPPRGD2: A PET Radiopharmaceutical Agent for Imaging αvβ3Integrin Levels

(2011) Erik S. Mittra et al.   RADIOLOGY

Noninvasive imaging of tumor integrin expression using 18F-labeled RGD dimer peptide with PEG4 linkers

(2009) Zhaofei Liu et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

18F-Labeled Galacto and PEGylated RGD Dimers for PET Imaging of αvβ3 Integrin Expression

(2009) Shuanglong Liu et al.   MOLECULAR IMAGING AND BIOLOGY

Activation of tumor cell integrin  v 3 controls angiogenesis and metastatic growth in the brain

(2009) M. Lorger et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Use of a Novel Arg-Gly-Asp Radioligand, 18F-AH111585, to Determine Changes in Tumor Vascularity After Antitumor Therapy

(2008) M. S. Morrison et al.   JOURNAL OF NUCLEAR MEDICINE

Phase I Trial of the Positron-Emitting Arg-Gly-Asp (RGD) Peptide Radioligand 18F-AH111585 in Breast Cancer Patients

(2008) L. M. Kenny et al.   JOURNAL OF NUCLEAR MEDICINE

Patterns of  v 3 Expression in Primary and Metastatic Human Breast Cancer as Shown by 18F-Galacto-RGD PET

(2008) A. J. Beer et al.   JOURNAL OF NUCLEAR MEDICINE

Multimodality Molecular Imaging of Tumor Angiogenesis

(2008) W. Cai et al.   JOURNAL OF NUCLEAR MEDICINE